Pulse Therapeutics
Euphrates Vascular is a medical device company focused on addressing distal vascular occlusions, including conditions such as Acute Ischemic Stroke (AIS), Peripheral Artery Disease (PAD), and ST Elevated Myocardial Infarction (STEMI). The company develops innovative nanotechnology-based systems, such as the Pulse NanoMED, to improve diagnosis and treatment of complex vascular occlusions, aiming for more comprehensive reperfusion, better health economics, and life-saving outcomes.
Industries
Nr. of Employees
small (1-50)
Pulse Therapeutics
St Louis, Missouri, United States, North America
Products
Nanoscale magnetically-actuated interventional system
An integrated system comprising an external rotating magnetic workstation and intravenously administered iron-oxide nanoparticles engineered to accelerate delivery of thrombolytic agents to distal vascular occlusions and to improve reperfusion in stroke, peripheral arterial disease and myocardial infarction.
Nanoscale magnetically-actuated interventional system
An integrated system comprising an external rotating magnetic workstation and intravenously administered iron-oxide nanoparticles engineered to accelerate delivery of thrombolytic agents to distal vascular occlusions and to improve reperfusion in stroke, peripheral arterial disease and myocardial infarction.
Services
Collaborative research and clinical partnerships
Partnerships for preclinical and early clinical evaluation of magnetically-actuated nanoparticle therapies; engagement with hospitals and research organizations for trials and technology assessment.
Regulatory and government-award compliance support
Institutional capability to manage disclosure, training and reporting requirements for PHS/NIH-funded research including FCOI procedures and reporting to awarding agencies.
Support for early feasibility clinical trials and regulatory submissions
Activities supporting filing and initiation of early-stage clinical investigations including IDE preparation and site-based evaluations.
Collaborative research and clinical partnerships
Partnerships for preclinical and early clinical evaluation of magnetically-actuated nanoparticle therapies; engagement with hospitals and research organizations for trials and technology assessment.
Regulatory and government-award compliance support
Institutional capability to manage disclosure, training and reporting requirements for PHS/NIH-funded research including FCOI procedures and reporting to awarding agencies.
Support for early feasibility clinical trials and regulatory submissions
Activities supporting filing and initiation of early-stage clinical investigations including IDE preparation and site-based evaluations.
Expertise Areas
- Nanomedicine drug delivery
- Interventional vascular device development
- Acute ischemic stroke therapy
- Peripheral arterial disease and critical limb ischemia therapy
Key Technologies
- Magnetically-actuated nanoparticle drug delivery
- Iron-oxide nanoparticle / microbead formulations
- Rotating external magnetic field actuation
- Magnetically-enhanced mixing for thrombolysis